Trial · NCT04719650
Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid
NCT04719650, Phase 4, Unknown, Peking University Third Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid. Trials, record NCT04719650. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04719650
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid
- NCT number
- NCT04719650
- Status
- Unknown
- Phases
- Phase 4
- Enrollment
- 64 participants, estimated
- Lead sponsor
- Peking University Third Hospital
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Zoledronic Acid Injection, Zoledronic Acid Injection, Zoledronic Acid Injection, Placebo
- First posted
- 2021-01-22
- Last updated
- 2021-06-23
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Concentration of Zoledronic acid | Predose, 30 minutes, 2 hours, 24 hours, day 7, day 29, 3 months, 6 months, 12 months, 24 months, and 36 months post dose | Zoledronic acid concentration in plasma and urine. |
| Primary | Maximum concentration of Zoledronic acid | 0-36 months | The observed maximum concentration following administration (Cmax) in plasma after zoledronic acid infusion. |
| Primary | Time to reach maximum concentration of Zoledronic acid | 0-36 months | The time to reach the maximum concentration after administration (Tmax) in plasma after zoledronic acid infusion. |
| Primary | AUC of Zoledronic acid | 0-36 months | The area under the concentration-time curve (AUC) in plasma after zoledronic acid infusion. |
| Primary | terminal half-life of Zoledronic acid | 0-36 months | The terminal half-life (t1/2) of zoledronic acid after administration. |
| Primary | apparent clearance of Zoledronic acid | 0-36 months | The apparent clearance (CL/F) of zoledronic acid after administration. |
| Primary | apparent volume of distribution of Zoledronic acid | 0-36 months | The apparent volume of distribution of zoledronic acid after administration. |
| Primary | Concentration of bone turnover markers | 0-36 months | Concentration-time profile of procollagen type 1 N-propeptide (P1NP), bone-specific alkaline phosphatase (ALP), osteocalcin (OCN), C-telopeptide (CTx), and tartrate-resistant acid phosphatase 5b (TRACP-5b) with unit of ng/mL. |
| Primary | Concentration of 25(OH)D and FGF23 | 0-36 months | Concentration determination of 25(OH)D and fibroblast growth factor 23 (FGF23) with unit of ng/mL |
| Primary | PTH concentration determination | 0-36 months | Assessment of the profile of parathyroid hormone (PTH) |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04719650
GET https://conductscience.org/api/trials/v1/NCT04719650/registered?page=2